JC

James Calloway

Financial Reporter

James Calloway is a financial reporter at StockTi covering corporate earnings, regulatory policy, and market-moving events. A former business journalist with Reuters, James has covered financial markets for over eight years across New York and Washington. He specializes in breaking down earnings reports, SEC filings, and policy decisions that affect publicly traded companies and investor portfolios.

Earnings, Regulation 1,789 articles

Articles by James Calloway

FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares
Regulation

FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares

Eli Lilly stock gained 3.7% after FDA signaled action against telehealth firm Hims & Hers over $49 compounded weight-loss alternatives. Regulatory uncertainty continues to impact obesity drug market valuations.

LLY